# Terran Biosciences

> Terran Biosciences is a platform biotech developing therapeutics and technologies for neurological and psychiatric disease. It runs one of the industry's largest psychedelic development programs - psilocybin, LSD, MDMA derivatives and novel prodrugs - alongside late-stage schizophrenia assets licensed from Sanofi and Pierre Fabre, GMP psychedelic manufacturing, and NM-101, an FDA-cleared cloud platform for neuromelanin MRI analysis.

- **Founded:** 2017
- **Headquarters:** Miami, Florida, United States
- **Founders:** Sam Clark (Founder & CEO (MD, PhD))
- **Team size:** ~5 employees
- **Products:** Psychedelics Program, TerXT, Idazoxan XR, Eplivanserin & Volinanserin, NM-101
- **Notable:** Received FDA clearance for NM-101, the first cloud-based neuromelanin MRI analysis platform., Obtained USPTO notice of allowance for novel psilocybin salts (psilocybin HCl and psilocybin edisylate)., Secured a worldwide licensing deal with Sanofi for two late-stage CNS assets.

## Products & services

- **Psychedelics Program** — One of the industry's largest psychedelic development programs, spanning psilocybin, LSD, DOM, 2C-B, MDMA and empathogen derivatives, plus novel prodrugs (orally active DMT and 5-MeO-DMT, long-acting MDMA) and non-hallucinogenic psychoplastogens.
- **TerXT** — Xanomeline and trospium prodrugs for schizophrenia with once-daily dosing and a long-acting injectable option.
- **Idazoxan XR** — Alpha-2 adrenergic receptor antagonist for schizophrenia and Alzheimer's disease, licensed from Pierre Fabre.
- **Eplivanserin & Volinanserin** — Phase 3 serotonin 2A receptor antagonists for neuropsychiatric conditions, licensed from Sanofi.
- **NM-101** — First FDA-cleared, cloud-based software platform that analyzes neuromelanin MRI scans for clinicians (AI software as a medical device).
- **GMP Psychedelic Manufacturing** — Manufacturing and global supply of GMP-grade psychedelic compounds to researchers and treatment centers.
- **Novel Psilocybin Salts** — Patent-allowed psilocybin HCl and psilocybin edisylate - described as the world's first new salts and polymorphs of psilocybin.

## Achievements

- Received FDA clearance for NM-101, the first cloud-based neuromelanin MRI analysis platform.
- Obtained USPTO notice of allowance for novel psilocybin salts (psilocybin HCl and psilocybin edisylate).
- Secured a worldwide licensing deal with Sanofi for two late-stage CNS assets.
- Licensed idazoxan from Pierre Fabre for CNS indications.
- Built one of the largest psychedelic development programs in the industry.
- Founder credited with 200+ patent applications across neuropsychiatry.

## Latest updates

- **2024-02** — Reported funding activity (~$12.8M total, Series B stage) with backing from Valhalla Ventures and Tabula Rasa Ventures.
- **2024** — Founder Sam Clark recognized as a PM360 ELITE Disruptor.
- **2023** — Notice of allowance from USPTO for novel psilocybin salts and polymorphs.

## Links

- Website: https://terranbiosciences.com
- LinkedIn: https://www.linkedin.com/company/terran

---

Profile page: https://yespress.io/terran-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-08